Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

64 results
Display

Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer

Jo J, Kim SH, Kim YJ, Lee J, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Chung JH, Jeon YK, Lee JS

PURPOSE: Previous retrospective studies suggest that anaplastic lymphoma kinase (ALK) mutation-positive (ALK+) non-small cell lung cancer (NSCLC) patients are sensitive to pemetrexed. To determine its efficacy, we retrospectively evaluated clinical...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference

Jang JY, Yanaihara , Pujade-Lauraine E, Mikami Y, Oda K, Bookman M, Ledermann , Shimada M, Kiyokawa T, Kim BG, Matsumura , Kaku T, Kuroda T, Nagayoshi , Kawabata A, Iida Y, Kim JW, Quinn M, Okamoto A

There has been significant progress in the understanding of the pathology and molecular biology of rare ovarian cancers, which has helped both diagnosis and treatment. This paper provides an update...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Inhibition of autophagy protein LC3A as a therapeutic target in ovarian clear cell carcinomas

Miyamoto M, Takano M, Aoyama T, Soyama H, Yoshikawa , Tsuda H, Furuya K

OBJECTIVE: Ovarian clear cell carcinoma (CCC) is one of histological subtypes showing poor prognosis due to chemoresistance. The association of autophagy-related proteins and clinical implementation in CCC has not been...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Role of Common Pharmaceutical Agents on the Prevention and Treatment of Pancreatic Cancer

Amin S, Boffetta P, Lucas AL

Survival from pancreatic cancer remains poor. Conventional treatment has resulted in only marginal improvements in survival compared with survival in the previous several decades. Thus, considerable interest has emerged regarding...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Immune checkpoint blockade therapy for bladder cancer treatment

Kim J

Bladder cancer remains the most immunogenic and expensive malignant tumor in the United States today. As the 4th leading cause of death from cancer in United States, Immunotherapy blocking immune...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Structural Equation Model on Resilience of Breast Cancer Patients Receiving Chemotherapy

Yang JH, Kim OS

PURPOSE: The purpose of this study was to construct and test a structural equation model on resilience of breast cancer patients receiving chemotherapy. METHODS: Participants were 204 patients with breast cancer...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Potential role for metformin in urologic oncology

Sayyid RK, Fleshner N

Metformin is one of the most commonly used drugs worldwide. It is currently considered first-line pharmacological agent for management of diabetes mellitus type 2. Recent studies have suggested that metformin...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Systemic Chemotherapy in Advanced Pancreatic Cancer

Lee HS, Park SW

Pancreatic cancer remains one of the most lethal cancers. These patients often have multiple symptoms, and integrated supportive care is critical in helping them remain well for as long as...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer

Lee M, Chang MY, Yoo H, Lee KE, Chay DB, Cho H, Kim S, Kim YT, Kim JH

PURPOSE: To determine the most powerful cancer antigen 125 (CA125)-related prognostic factor for advanced epithelial ovarian cancer (EOC) and to identify cut-off values that distinguish patients with a poor prognosis...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis

Lee JM, Jang BK, Lee YJ, Choi WY, Choi SM, Chung WJ, Hwang JS, Kang KJ, Kim YH, Chauhan AK, Park SY, Tak WY, Kweon YO, Kim BS, Lee CH

BACKGROUND/AIMS: Treating hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remains controversial. We compared the outcomes of hepatic resection (HR), transarterial chemoembolization (TACE), and sorafenib therapy as treatments for...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Transcatheter Arterial Chemoembolization Plus ¹³¹I-Labelled Metuximab versus Transcatheter Arterial Chemoembolization Alone in Intermediate/Advanced Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Zhu ZX, Liao MH, Wang XX, Huang JW

OBJECTIVE: The aim of the study was to compare transcatheter arterial chemoembolization (TACE) plus ¹³¹I-labelled metuximab with TACE alone for hepatocellular carcinoma (HCC). MATERIALS AND METHODS: A comprehensive search was conducted...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Complete recovery of pyoderma gangrenosum after successful treatment of underlying hairy cell leukemia with cladribine

Tombak A, Aygun S, Serinsoz E, Tiftik EN

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy

Park JG

BACKGROUND/AIMS: Sorafenib is currently the sole molecular targeted agent that improves overall survival in advanced hepatocellular carcinoma (HCC). Despite the efficacy of sorafenib, the response rate varies in patients with...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine

Kim HS, Sung YJ, Paik S

Since the first human cancer cell line, HeLa, was established in the early 1950s, there has been a steady increase in the number and tumor type of available cancer cell...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Trends in the Use of Chemotherapy before and after Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer in Korea

Kim SH, Seo HK, Shin HC, Chang SJ, Yun S, Joo J, Ku JH, Kim HS, Jeon HG, Jeong BC, Jeong IG, Kang SH, Hong B, UCART (urothelial cancer-advanced research and treatment group in Korea) group

We investigated trends in perioperative chemotherapy use, and determined factors associated with neoadjuvant chemotherapy (NAC) and adjuvant chemotherapy (AC) use in Korean patients with muscle-invasive bladder cancer (MIBC). We recruited...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Treatment Response Evaluation of Breast Cancer after Neoadjuvant Chemotherapy and Usefulness of the Imaging Parameters of MRI and PET/CT

An YY, Kim SH, Kang BJ, Lee AW

This study was aimed to evaluate the ability of imaging parameters measured on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), diffusion-weighted MRI (DWI) and positron emission tomography/computed tomography (PET/CT) to serve...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
An important role for peroxiredoxin II in survival of A549 lung cancer cells resistant to gefitinib

Kwon T, Rho JK, Lee JC, Park YH, Shin HJ, Cho S, Kang YK, Kim BY, Yoon DY, Yu DY

Redox adaptation is an important concept that explains the mechanisms by which cancer cells survive under persistent endogenous oxidative stress and become resistant to certain anticancer agents. To investigate this...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy

Wang F, Lou JF, Cao Y, Shi XH, Wang P, Xu J, Xie EF, Xu T, Sun RH, Rao JY, Huang PW, Pan SY, Wang H

MicroRNAs (miRNAs), a class of small non-coding RNAs, mediate gene expression by either cleaving target mRNAs or inhibiting their translation. They have key roles in the tumorigenesis of several cancers,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Sorafenib in the Treatment of Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Report of Four Cases

Hong YM, Yoon KT, Cho M, Kang DH, Kim HW, Choi CW, Park SB, Heo J, Woo HY, Lim W

With an increasing number of patients with hepatocellular carcinoma (HCC) undergoing liver transplantation (LT), tumor recurrence remains the main limiting factor for long-term survival. Although sorafenib is available for advanced...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Is Intravesical Bacillus Calmette-Guerin Therapy Superior to Chemotherapy for Intermediate-risk Non-muscle-invasive Bladder Cancer?: An Ongoing Debate

Han KS, You D, Jeong IG, Kwon T, Hong B, Hong JH, Ahn H, Ahn TY, Kim CS

The objective of this study was to evaluate the risk of recurrence in patients with intermediate-risk non-muscle-invasive bladder cancer (NMIBC) after intravesical instillation with chemotherapeutic agents or Bacillus Calmette-Guerin (BCG)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr